source
- Novo and Pfizer say MFN pricing agreements remain unchanged despite Democratic gains in CongressOn their third‑quarter earnings calls, the CEOs of Novo Nordisk and Pfizer said the Most Favored Nation drug‑pricing contracts they signed under the previous administration are still in effect and…
- Sanofi halts development of Nurix's STAT6 degrader programSanofi announced it will stop work on an experimental drug that targets STAT6, a protein involved in immune signaling. The compound, known as SAR448272 and developed in partnership with Nurix, was…